Physician profile
Mark Beylin
NPI 1356391601
$6,471.58
in general payments reported to CMS, 2019-2025
24 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,205 · 2020: $427 · 2021: $1,096 · 2022: $466 · 2023: $2,307 · 2024: $500 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,825 · Food and Beverage: $1,453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,825.25 |
| Food and Beverage | $1,452.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $3,962.63 | 2019-2025 | Infinity, Augment Injectable, Axsos |
| Paragon 28, INC. | $451.09 | 2024 | Apex 3d |
| Organogenesis INC. | $390.36 | 2019-2023 | Puraply |
| Wright Medical Technology, INC. | $375.61 | 2019-2020 | |
| Bioventus LLC | $211.36 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $156.43 | 2022 | |
| Boston Scientific Corporation | $146.22 | 2025 | Ranger |
| Merck Sharp & Dohme LLC | $120.11 | 2019 | |
| Cardiovascular Systems INC. | $101.24 | 2021 | |
| Kci USA, INC. | $98.04 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $65.46 | 2024-2025 | Nuzyra |
| Smith+Nephew, INC. | $64.25 | 2022-2025 | Collagenase Santyl |
| Next Science LLC | $62.40 | 2022-2023 | Xperience, Blastx, Surgx |
| Orthofix Medical, INC. | $42.34 | 2021-2022 | |
| Embody, INC. | $39.72 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $36.80 | 2019-2020 | |
| Integra Lifesciences Corporation | $29.59 | 2022 | |
| Horizon Therapeutics Plc | $24.41 | 2022 | |
| Grt US Holding, INC. | $18.21 | 2021 | |
| Tactile Systems Technology INC | $17.73 | 2025 | Flexitouch Plus, Nimbl |
| Solventum Corporation | $16.73 | 2024 | Activ.A.C., Kerramax Care, Promogran Prisma |
| Pacira Pharmaceuticals Incorporated | $16.04 | 2019 | |
| Mimedx Group, INC. | $14.46 | 2025 | |
| Arteriocyte Medical Systems, INC. | $10.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Beylin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.